Europe Ophthalmic Drugs & Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers European Ophthalmology Pharmaceutical Companies and the market is Segmented by Product (Devices, and Drugs), Disease (Glaucoma, Cataract, Age-related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Other Diseases), and Geography (Germany, UK, France, Italy, Spain and the Rest of Europe). The report offers the value (in USD Million) for the above segments.

Europe Ophthalmic Drugs & Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Ophthalmic Drugs and Devices Market Size

View Global Report
Europe Ophthalmology Drug and Device Market Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2021 - 2023
CAGR 5.30 %
Market Concentration Medium

Major Players

Europe Ophthalmology Drug and Device Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Europe Ophthalmology Drug and Device Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Europe Ophthalmic Drugs and Devices Market Analysis

The Europe Ophthalmology Drug and Device Market is expected to register a CAGR of 5.3% during the forecast period.

COVID-19 has affected the world and has had a significant impact on the healthcare system. The COVID-19 outbreak has resulted in many changes in European healthcare practice, especially ophthalmology drugs and devices in Europe majorly impacted. The elective operations/therapies and non-emergency medical procedures had nearly halted in most medical centers, and these services witnessed a significant decline, including cataract and vitreoretinal surgeries. An article by the European Journal of Ophthalmology published in March 2021 reported that the epidemic severely struck ophthalmic surgical procedures in Italy and other European countries. The article also reported that eye surgical procedures were limited to urgent procedures and intravitreal injections in all centers due to government rules. Thus, although an overall reduction in elective, urgent, and intravitreal injection procedures was observed during the lockdown period in the European countries, however after a post-pandemic, the market witnessed significant growth as these services got resumed.

The growth of the market is driven by the factors such as the growing prevalence of eye disease, technological advancements in the field of ophthalmology, and the rising geriatric population. The growing prevalence of eye disease in Europe is driving the market. For instance, according to a study published in the European Journal of Opthalmology in March 2021, an article reported that myopia is predicted to become the most common cause of irreversible vision impairment and blindness in Europe. Similarly, as per the article published in the Journal of Glaucoma in August 2022 reported that primary open-angle glaucoma is a neurodegenerative disease highly prevalent in the European adult population, with cases expected to increase over the aging population is expected to increase in European countries. Thus, a high incidence of eye disorders is increasing the demand for medicines and related surgeries, which is expected to boost market growth over the forecast period.

The technological advancement in ophthalmic devices in Europe is also driving the market. For instance, in September 2022, BVI received the certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its notified body, the British Standards Institution (BSI). The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Additionally, in September 2022, SIFI launched Evolux, a novel extended monofocal intraocular lens (IOL) based on a hydrophobic material and a non-diffractive profile designed to provide better intermediate vision. Evolux was developed on a patented technology platform, pioneering the extension of the depth of focus through wavefront engineering. Thus, such product development and launches in Europe are expected to drive market growth.

Thus, all factors mentioned above, such as the rising prevalence of ophthalmic diseases and technological advancement in ophthalmology devices, are expected to boost the market over the forecast period. However, the high risk associated with eye surgery and stringent regulations may restrain the market growth over the forecast period.

Europe Ophthalmic Drugs and Devices Industry Overview

The Europe ophthalmology drug and devices market is fragmented due to the presence of fewer companies at the global and regional levels. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known as Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Essilor International SA, Haag-Streit Group, Johnson & Johnson, Nidek Co. Ltd, Topcon Corporation, Ziemer Group AG, Staar Surgical, Inc., Novartis International AG, Pfizer Inc, and Roche Holding Ltd.

Europe Ophthalmic Drugs and Devices Market Leaders

  1. Topcon Corporation

  2. Johnson & Johnson

  3. Carl Zeiss Meditec AG

  4. Pfizer

  5. Nidek Co. Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Europe Ophthalmology Drug and Device Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Europe Ophthalmic Drugs and Devices Market News

  • In September 2022, European Commission (EC) approved Roche's Vabysmo. It is one of the first bispecific antibodies for the treatment of neovascular or 'wet' age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).
  • In August 2022, the European Commission (EC) granted marketing authorization for Ranivisio (ranibizumab), a biosimilar to Lucentis, for the treatment of age-related macular degeneration (AMD).

Europe Ophthalmic Drugs and Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Eye Disease
    • 4.2.2 Technological Advancements in the Field of Ophthalmology
    • 4.2.3 Rising Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 High Risk Associated with Eye Surgery
    • 4.3.2 Stringent Regulations
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Devices
    • 5.1.1.1 Surgical Devices
    • 5.1.1.1.1 Intraocular Lenses
    • 5.1.1.1.2 Ophthalmic Lasers
    • 5.1.1.1.3 Other Surgical Devices
    • 5.1.1.2 Diagnostic Devices
    • 5.1.2 Drugs
    • 5.1.2.1 Glaucoma Drugs
    • 5.1.2.2 Retinal Disorder Drugs
    • 5.1.2.3 Dry Eye Drugs
    • 5.1.2.4 Allergic Conjunctivitis and Inflammation Drugs
    • 5.1.2.5 Other Drugs
  • 5.2 By Disease
    • 5.2.1 Glaucoma
    • 5.2.2 Cataract
    • 5.2.3 Age-related Macular Degeneration
    • 5.2.4 Inflammatory Diseases
    • 5.2.5 Refractive Disorders
    • 5.2.6 Other Diseases
  • 5.3 Geography
    • 5.3.1 Germany
    • 5.3.2 United Kingdom
    • 5.3.3 France
    • 5.3.4 Italy
    • 5.3.5 Spain
    • 5.3.6 Rest of Europe

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alcon Inc.
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 Carl Zeiss Meditec AG
    • 6.1.4 Essilor International SA
    • 6.1.5 Haag-Streit Group
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Nidek Co. Ltd
    • 6.1.8 Topcon Corporation
    • 6.1.9 Ziemer Group AG
    • 6.1.10 Staar Surgical
    • 6.1.11 Novartis International AG
    • 6.1.12 Pfizer Inc
    • 6.1.13 Roche Holding Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Ophthalmic Drugs and Devices Industry Segmentation

As per the scope of the report, ophthalmic drugs are administered to the eyes, most typically as an eye drop formulation. These topical formulations are used to combat a multitude of diseased states of the eye and ophthalmic devices are medical equipment designed for diagnosis, surgery, and vision correction. These devices gain increased importance and adoption due to the high prevalence of various ophthalmic diseases such as glaucoma, cataract, and other vision-related issues. The Europe Ophthalmology Drug and Devices Market is Segmented by Product (Devices (Surgical Devices (Intraocular Lenses, Ophthalmic Lasers, Other Surgical Devices), Diagnostic Devices), Drugs (Glaucoma Drugs, Retinal Disorder Drugs, Dry Eye Drugs, Allergic Conjunctivitis, and Inflammation Drugs, and Other Drugs)), Disease (Glaucoma, Cataract, Age-related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Other Diseases) and Geography (Germany, United Kingdom, France, Italy, Spain and the Rest of Europe). The report offers the value (in USD million) for the above segments.

By Product Type Devices Surgical Devices Intraocular Lenses
Ophthalmic Lasers
Other Surgical Devices
Diagnostic Devices
Drugs Glaucoma Drugs
Retinal Disorder Drugs
Dry Eye Drugs
Allergic Conjunctivitis and Inflammation Drugs
Other Drugs
By Disease Glaucoma
Cataract
Age-related Macular Degeneration
Inflammatory Diseases
Refractive Disorders
Other Diseases
Geography Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Europe Ophthalmic Drugs and Devices Market Research FAQs

What is the current Europe Ophthalmology Drug and Device Market size?

The Europe Ophthalmology Drug and Device Market is projected to register a CAGR of 5.3% during the forecast period (2025-2030)

Who are the key players in Europe Ophthalmology Drug and Device Market?

Topcon Corporation, Johnson & Johnson, Carl Zeiss Meditec AG, Pfizer and Nidek Co. Ltd are the major companies operating in the Europe Ophthalmology Drug and Device Market.

What years does this Europe Ophthalmology Drug and Device Market cover?

The report covers the Europe Ophthalmology Drug and Device Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Europe Ophthalmology Drug and Device Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Lyophilization Equipment and Services Industry Report

Statistics for the 2025 Europe Ophthalmology Drug and Device market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Ophthalmology Drug and Device analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.